1. 29TiPA translational study to discover novel host-related immune-biomarkers for nivolumab (Nivo) in advanced gastric cancer (GC): JACCRO GC-08 (DELIVER trial). (17th December 2018) Authors: Sunakawa, Y; Muro, K; Nakajima, T E; Kawakami, H; Inoue, E; Matoba, R; Sato, Y; Ichikawa, W; Fujii, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 483PA biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3. (23rd October 2018) Authors: Sunakawa, Y; Stintzing, S; Cao, S; Luecke, J; Thompson, D; Moran, M; Astrow, S H; Hsiang, J; Stephens, C; Zhang, W; Tsuji, A; Takahashi, T; Denda, T; Shimada, K; Kochi, M; Takeuchi, M; Fujii, M; Ichikawa, W; Heinemann, V; Lenz, H-J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 685PRelation of overall survival, progression free survival, post progression survival and response rate in four randomized Japanese phase III trials comparing various combinations of S-1 therapy for first-line treatment of advanced gastric cancer. (23rd October 2018) Authors: Takeuchi, M; Ichikawa, W; Shitara, K; Sunakawa, Y; Oba, K; Koizumi, W; Sakata, Y; Furukawa, H; Takeuchi, M; Fujii, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P-243Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy. (20th June 2018) Authors: Tsuji, A; Nakamura, M; Watanabe, T; Manaka, D; Matsuoka, H; Kataoka, M; Takeuchi, M; Ichikawa, W; Fujii, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P-243Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy. (20th June 2018) Authors: Tsuji, A; Nakamura, M; Watanabe, T; Manaka, D; Matsuoka, H; Kataoka, M; Takeuchi, M; Ichikawa, W; Fujii, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PD-013RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC). (2nd July 2019) Authors: Sunakawa, Y; Nakamura, M; Ishizaki, M; Kataoka, M; Satake, H; Kitazono, M; Yanagisawa, H; Kawamoto, Y; Kuramochi, H; Ohori, H; Nakamura, M; Takahashi, K; Maeda, F; Komeno, C; Takeuchi, M; Fujii, M; Yoshino, T; Ichikawa, W; Tsuji, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗